COR Announces Over 20 Presentations on INTEGRILIN -eptifibatide- Injection to be Featured at the Upcoming American Heart Association Scientific Sessions.

Business Editors/Medical Writers

SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Nov. 8, 2000

COR Therapeutics, Inc. (Nasdaq: CORR) announced today that its lead product, INTEGRILIN(R) (eptifibatide) Injection, will be featured in over 20 oral, poster, and satellite symposia presentations in association with the 2000 Scientific Sessions of the American Heart Association in New Orleans, Louisiana on November 12-15.

All presentations are open to all registrants for the meeting. A comprehensive list of presentations relevant to COR is available on the COR website beginning Thursday, November 9 at www.corr.com. Notable presentations referencing the GP IIb-IIIa inhibitor class in general, and INTEGRILIN in particular, are as follows:

-- Percutaneous Coronary Intervention (PCI)

Due to protracted institutional review board and data collection processes at some institutions, not all of the ESPRIT 6-month patient case report forms have been submitted to the Duke Clinical Research Institute, the independent coordinating center for ESPRIT. In order to assure the integrity of the 6-month data, the results for the individual drug treatment arms will not be unblinded or analyzed until data collection is complete. As soon as the data collection process is complete, the 6-month ESPRIT results will be unblinded, analyzed, and made public.

On Tuesday, November 14 at 2:30 p.m., James E. Tcheng, MD, the Principal Investigator for ESPRIT from Duke University Medical Center (Durham, NC), will present blinded, preliminary, 6-month outcomes data available to date for the combined INTEGRILIN plus placebo cohort. The blended event rates for specific demographic populations (i.e. diabetics, females, older patients) will be compared and contrasted with the outcomes for the combined patient cohort at 30 days to ascertain the extent of adverse outcomes that occur over time in various patient populations in the modern era of PCI.

Several significant subset analyses from the 30-day ESPRIT data set will be presented at the AHA scientific sessions, examining outcomes with INTEGRILIN in diabetic patients (Marino Labinaz, MD, Tuesday, November 14 at 2:00 p.m.), female patients (Laura S. Fernandez, MD, Wednesday, November 15 at 11:15 a.m.), and those receiving low-dose heparin (Thaddeus R. Tolleson, MD, Tuesday, November 14 at 2:45 p.m.).

C. Michael Gibson, MD, from the University of California at San Francisco (San Francisco, CA) will present findings from the ESPRIT angiographic sub-study examining preservation of microvascular blood flow to heart muscle following PCI with INTEGRILIN. The oral presentation is scheduled for Sunday, November 12 at 4:45 p.m.

-- Unstable Angina/Non-ST Elevation Myocardial Infarction

Featured throughout the sessions will be discussions of new ACC/AHA guidelines for the management of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI). At a satellite symposium sponsored by COR and its marketing partner for INTEGRILIN, Key Pharmaceuticals, Inc., scheduled for 7:30 p.m. on Sunday, November 12 at the Hilton Riverside Hotel, Eugene Braunwald, MD of the Brigham and Women's Hospital (Boston, MA) and one of the primary authors of the guidelines, will discuss recommendations for the early use of GP IIb-IIIa inhibitors in UA/NSTEMI. At the same session, Robert Harrington, MD, of Duke University Medical Center (Durham, NC), will present data demonstrating the potential usefulness of INTEGRILIN when employed in a manner consistent with the guidelines.

-- ST-segment Elevation Myocardial Infarction

Progress to date with INTEGRILIN in combination with reduced doses of the fibrinolytics alteplase and tenecteplase will be discussed by Eric Topol, MD of the Cleveland Clinic Foundation (Cleveland, OH), and Robert Guilliano, MD of the Brigham and Women's Hospital at the COR/Key supported satellite symposium on Sunday evening.

The final results of the Phase II dose-confirmation phase of the INTRO-AMI study of INTEGRILIN combined with reduced-dose alteplase in ST elevation myocardial infarction will be formally presented at an oral abstract session by Sorin Brenner, MD of the Cleveland Clinic Foundation on Tuesday, November 14 at 10:30 a.m.

-- Platelet Biology

A discussion of the pro-inflammatory effects of platelets, the potential anti-inflammatory properties of GP IIb-IIIa inhibitors, and their relationship to inhibition of platelet aggregation will be presented on Sunday, November 12 at 9:35 a.m. by David Phillips, PhD, Principal Scientist at COR Therapeutics, who pioneered research into the platelet receptor GP IIb-IIIa. Several oral and poster presentations will highlight the platelet aggregation inhibitory effects of INTEGRILIN throughout the scientific sessions as follows:

- Frank V. Aguirre, MD of Prairie Cardiovascular Consultants (Springfield, IL)
on Monday, November 13 at 9:00 a.m.

- Christopher B. Liu, MD of Brigham and Women's Hospital on Monday, November 13
at 11:00 a.m.

- Samin K. Sharma, MD of Mt. Sinai Hospital (New York, NY) on Tuesday, November
14 at 2:15 p.m.

INTEGRILIN(R) (eptifibatide) Injection

INTEGRILIN is approved for marketing by the U.S. Food and Drug Administration (FDA). INTEGRILIN has the broadest range of approved indications among GP IIb-IIIa inhibitors available in the United States. INTEGRILIN is indicated for the treatment of patients with Acute Coronary Syndrome (unstable angina and non-Q-wave myocardial infarction) including patients who are to be managed medically and those undergoing PCI. INTEGRILIN is also indicated for the treatment of patients undergoing PCI at the time of the procedure.

INTEGRILIN is contraindicated in the following patient populations: those with a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days; severe hypertension (systolic blood pressure greater than 200 mm Hg or diastolic blood pressure greater than 110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding six weeks; history of stroke within 30 days or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb-IIIa inhibitor; platelet count less than 100,000 per cubic millimeter; serum creatinine greater than or equal to 4.0 mg/dL; dependency on renal dialysis; or known hypersensitivity to any component of the product.

COR Therapeutics, Inc. and Schering-Plough Corporation (NYSE:SGP) are worldwide development partners for INTEGRILIN. Both companies market and sell the drug in the United States. Schering-Plough markets INTEGRILIN in Europe. COR has the right to co-promote INTEGRILIN in Europe at a later date.

COR Therapeutics, Inc. is dedicated to the discovery, development, and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. COR has complementary research and development programs that seek to address critical needs in severe cardiovascular care, including unstable angina, acute myocardial infarction, deep vein thrombosis, and restenosis.

In addition to historical information, this press release contains forward-looking statements regarding the Company's performance that involve risks and uncertainties. Actual results may differ materially from the anticipated results discussed in such forward-looking statements, due to factors such as results of clinical trials with INTEGRILIN(R) (eptifibatide) Injection and other factors discussed in the Company's SEC reports, including, but not limited to, the Company's Report on Form 10-Q for the quarter ended September 30, 2000, and Report on Form 10-K for the year ended December 31, 1999. Forward-looking statements are based on our current expectations and the Company does not intend to update such information to reflect later events or developments.